Inducement of ER Stress by PAD Inhibitor BB-Cl-Amidine to Effectively Kill AML Cells

Abstract

Objective

Acute myeloid leukemia (AML) is a highly heterogeneous and recurrent hematological malignancy. Despite the emergence of novel chemotherapy drugs, AML patients’ complete remission (CR) remains unsatisfactory. Consequently, it is imperative to discover new therapeutic targets or medications to treat AML. Such epigenetic changes like DNA methylation and histone modification play vital roles in AML. Peptidylarginine deminase (PAD) is a protein family of histone demethylases, among which the PAD2 and PAD4 expression have been demonstrated to be elevated in AML patients, thus suggesting a potential role of PADs in the development or maintenance of AML and the potential for the identification of novel therapeutic targets.

Methods

AML cells were treated in vitro with the pan-PAD inhibitor BB-Cl-Amidine (BB-Cl-A). The AML cell lines were effectively induced into apoptosis by BB-Cl-A. However, the PAD4-specific inhibitor GSK484 did not.

Results

PAD2 played a significant role in AML. Furthermore, we found that BB-Cl-A could activate the endoplasmic reticulum (ER) stress response, as evidenced by an increase in phosphorylated PERK (p-PERK) and eIF2α (p-eIF2α). As a result of the ER stress activation, the BB-Cl-A effectively induced apoptosis in the AML cells.

Conclusion

Our findings indicated that PAD2 plays a role in ER homeostasis maintenance and apoptosis prevention. Therefore, targeting PAD2 with BB-Cl-A could represent a novel therapeutic strategy for treating AML.

Keywords

acute myeloid leukemia / BB-Cl-Amidine / peptidylarginine deminase / endoplasmic reticulum stress / apoptosis

References

[1] DohnerH, WeisdorfDJ, BloomfieldCD. Acute Myeloid Leukemia. N Engl J Med, 2015, 373(12): 1136-1152

[2] EsteyEH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol, 2018, 93(10): 1267-1291

[3] BewersdorfJP, ShallisR, StahlM, et al.. Epigenetic therapy combinations in acute myeloid leukemia: what are the options. Ther Adv Hematol, 2019, 10: 2040620718816 698

[4] AlqahtaniA, ChoucairK, AshrafM, et al.. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA, 2019, 5(3): FSO372

[5] CheungN, FungTK, ZeisigBB, et al.. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell, 2016, 29(1): 32-48

[6] NguyenAT, TaranovaO, HeJ, et al.. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood, 2011, 117(25): 6912-6922

[7] San Jose-EnerizE, Gimenez-CaminoN, AgirreX, et al.. HDAC Inhibitors in Acute Myeloid Leukemia. Cancers (Basel), 2019, 11(11): 1794

[8] TarighatSS, SanthanamR, FrankhouserD, et al.. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia, 2016, 30(4): 789-799

[9] GambacortaV, GnaniD, VagoL, et al.. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Front Cell Dev Biol, 2019, 7: 207

[10] WingelhoferB, SomervailleTCP. Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. Front Oncol, 2019, 9: 850

[11] MohananS, CherringtonBD, HoribataS, et al.. Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int, 2012, 2012: 895343

[12] ChangX, HanJ. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog, 2006, 45(3): 183-196

[13] NachatR, MechinMC, TakaharaH, et al.. Peptidylarginine deiminase isoforms 1–3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J Invest Dermatol, 2005, 124(2): 384-393

[14] YurttasP, VitaleAM, FitzhenryRJ, et al.. Role for PADI6 and the cytoplasmic lattices in ribosomal storage in oocytes and translational control in the early mouse embryo. Development, 2008, 135(15): 2627-2636

[15] WangY, WysockaJ, SayeghJ, et al.. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science, 2004, 306(5694): 279-283

[16] SongS, XiangZ, LiJ, et al.. A Novel Citrullinated Modification of Histone 3 and Its Regulatory Mechanisms Related to IPO-38 Antibody-Labeled Protein. Front Oncol, 2019, 9: 304

[17] FalcaoAM, MeijerM, ScaglioneA, et al.. PAD2-Mediated Citrullination Contributes to Efficient Oligodendrocyte Differentiation and Myelination. Cell Rep, 2019, 27(4): 1090-1102.e10

[18] McElweeJL, MohananS, GriffithOL, et al.. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer, 2012, 12: 500

[19] WangL, SongG, ZhangX, et al.. PADI2-Mediated Citrullination Promotes Prostate Cancer Progression. Cancer Res, 2017, 77(21): 5755-5768

[20] ChangX, FangK. PADI4 and tumourigenesis. Cancer Cell Int, 2010, 10: 7

[21] MoshkovichN, OchoaHJ, TangB, et al.. Peptidylarginine Deiminase IV Regulates Breast Cancer Stem Cells via a Novel Tumor Cell-Autonomous Suppressor Role. Cancer Res, 2020, 80(1): 2125-2137

[22] LedetMM, AndersonR, HarmanR, et al.. BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway. BMC Cancer, 2018, 18(1): 412

[23] SanoR, ReedJC. ER stress-induced cell death mechanisms. Biochim Biophys Acta, 2013, 1833(12): 3460-3470

[24] LiuLD, ZhangZW, MaYC, et al.. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib. J Transl Med, 2020, 18(1): 357

[25] XueT, LiuX, ZhangM, et al.. PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2-BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer. Adv Sci (Weinh), 2021, 8(6): 2002831

[26] WangY, LiP, WangS, et al.. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem, 2012, 287(31): 25941-25953

[27] WangS, ChenXA, HuJ, et al.. ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells. Mol Cancer Ther, 2015, 14(4): 877-888

[28] GuYH, WangY, BaiY, et al.. Endoplasmic reticulum stress and apoptosis via PERK-eIF2alpha-CHOP signaling in the methamphetamine-induced chronic pulmonary injury. Environ Toxicol Pharmacol, 2017, 49: 194-201

[29] MasciarelliS, CapuanoE, OttoneT, et al.. Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. Blood Adv, 2019, 3(24): 4155-4160

[30] LiP, LiM, LindbergMR, et al.. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med, 2010, 207(9): 1853-1862

[31] YuY, SuK. Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. J Clin Cell Immunol, 2013, 4: 139

[32] KnightJS, SubramanianV, O’DellAA, et al.. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis, 2015, 74(12): 2199-2206